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Abstract
Background: The insulin-like growth factor (IGF) system plays an important role in the development and progression
of cancer. However, little is known about the expression of the IGF system components and their clinicopathological
significance and prognostic value in nasopharyngeal carcinoma (NPC).
Methods: IGF system components (IGF-1, IGF-2, IGF-1SR, IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4 and IGFBP-6) were
quantified from the plasma of NPC patients and healthy individuals using the RayBio Human Cytokine Antibody Array.
IGFBP-1 and IGF-1 mRNA levels were quantified by real-time qPCR, and protein expression was detected by western
blot in nine NPC cell lines and four immortalized nasopharyngeal epithelial (NPE) cell lines. Tissue-specific expression of
IGFBP-1 and IGF-1 was detected by immunohistochemistry in paraffin-embedded NPC tissues. ELISA analysis was used
to measure the serum levels of IGFBP-1 and IGF-1 in 142 NPC patients and 128 healthy controls and determine
potential correlation with clinicopathological parameters.
Results: Significantly higher levels of circulating IGFBP-1 and lower levels of IGF-1 and IGF-2 were detected
in NPC patients compared to healthy controls by Cytokine Antibody Array analyses (P = 0.034, 0.012, 0.046, respectively).
IGFBP-1 expression was detected in the majority of NPC cell lines, but not in NPE cell lines, and was shown to localize
to the nucleus of tumour cells, in contrast to the cytoplasmic staining observed in normal cells. Importantly, IGFBP-1
expression was stronger in NPC tumour tissues compared to peritumoural tissues. In contrast, IGF-1 expression was
weak or absent in NPC and NPE cell lines, with the exception of the EBV-infected C666 cell line, and was found to be
expressed at lower levels in tumour tissues compared to tumour-adjacent normal tissue. Levels of serum IGFBP-1 were
shown to be significantly higher in patients with NPCs compared to healthy control individuals (55.23 ± 41.25 μg/L
vs. 32.08 ± 29.73 μg/L, P < 0.001), whereas serum levels of IGF-1 were significantly lower in NPC patients compared to
healthy controls (98.14 ± 71.48 μg/L vs. 164.01 ± 92.08 μg/L, P = 0.001). Consistently, the IGFBP-1/IGF-1 serum ratio was
shown to be significantly higher in NPC patients compared to healthy control individuals (P = 0.002). Serum levels of
IGFBP-1 and the IGFBP-1/IGF-1 ratio significantly correlated with age (P = 0.020; P = 0.016), WHO histological
classification (P = 0.044; P = 0.048), titre of EA (EB Virus Capsid Antigen-IgA) and NPC (P = 0.015; P = 0.016). In contrast,
higher IGFBP-1 serum levels and IGFBP-1/IGF-1 ratio significantly correlated with poor RFS (P = 0.046; P = 0.037) and
OS (P = 0.038; P = 0.009). Multivariate analysis revealed that the IGFBP-1/IGF-1 ratio, but not serum IGFBP-1 level,
represents an independent risk factor for poor RFS (P = 0.044) and OS (P = 0.035).
Conclusions: A higher IGFBP-1/IGF-1 serum ratio is significantly associated with poor prognosis in NPC patients.
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Background
Nasopharyngeal carcinoma (NPC) is a malignant head
and neck tumour with a distinct racial and geographical
distribution that is highly prevalent in Southeast Asia
[1]. Although radiotherapy and chemotherapy are effi-
cient therapeutic approaches for treating NPC, the dis-
ease remains a deadly due to late presentation of the
disease and poor prognosis. Because NPC tumours are
asymptomatic, advanced disease at time of diagnosis
and high rates of recurrence and metastasis underlie
the high mortality rate in NPC patients. Therefore,
finding new biomarkers or risk factors will contribute
to earlier diagnosis and better prognosis for NPC
patients.
The insulin-like growth factor (IGF) system consists of
a complex network of ligands (IGF-1 and 2), their cog-
nate receptors (IGFR-1 and 2), IGF-binding proteins
(IGFBP1-6), and IGFBP proteases. The IGF signalling
pathway, which facilitates communication between cells
and their physiologic environment, may be involved in
human cancer progression and can be targeted for thera-
peutic intervention [2]. Within the blood stream, IGF-1
is bound to IGFBPs and activates IGF-1R following its
release from the complex. The interaction between IGFs,
IGFBPs and IGFRs promotes cellular proliferation and
inhibits apoptosis [3].
Several studies have reported a correlation between
circulating levels of IGF-1 and IGFBP-1 in healthy
people and the risk of cancer development. IGF-1
plasma or serum levels have been reported to be in-
creased in patients with a variety of cancers, including
colorectal adenoma, malignant melanoma, breast cancer,
non-small cell lung cancer [4–6]. However, conflicting
results have been observed in studies conducted in
prostate cancer, epithelial ovarian cancer, breast can-
cer, and oral cancer [7–10]. In addition, serum levels
of IGFBP-1 have been reported to be increased in
metastatic prostate and oral cancers, but not in pan-
creatic, non-metastatic colorectal or endometrial can-
cers [11–13]. Despite considerable research, the role of
IGFs in cancer remains unclear, and clinical trials have
been unsuccessful [14]. Moreover, how IGF-1 and
IGFBP-1 are regulated at the expression level remains
equivocal in tumour tissues and within the circulating
blood stream.
In the present study, we examined the expression
patterns of IGF-1 and IGFBP-1 in different NPC and
normal nasopharyngeal epithelial (NPE) cells lines.
Furthermore, we assessed the serum levels of IGF-1
and IGFBP-1 in NPC patients and healthy control in-
dividuals and determined whether altered IGF-1 and
IGFBP-1 levels were associated with clinical outcome
to assess the potential value of IGF-1 or IGFBP-1 as a
prognostic biomarker for NPC.
Methods
Patients, blood and tissue samples
Plasma from 10 NPC patients and 10 healthy volunteers
were obtained in October 2012 and used for 8 IGF-
related cytokine arrays. Plasma samples were stored at
80 °C and were measured in 3 months.
Sera used for IGF-1 and IGFBP-1 arrays were obtained
from 143 patients with NPC between November 2005
and October 2008. The cohort consisted of 119 male pa-
tients and 24 female patients. Patients ranged in age
from 15 to 71 years (mean, 49.6 years). All sera and
plasma were collected from NPC patients at the time of
diagnosis and prior to tumour radiation therapy or sur-
gery. The 143 patient characteristics are described in
Table 1.
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Overall survival (OS) was defined as the interval be-
tween the date of surgery and the date of death or the
last known follow-up visit. Relapse-free survival (RFS)
was defined as the interval between the operation and
the date that tumour recurrence or metastasis was diag-
nosed. All follow-up data from the NPC patients used in
this study were available and complete. A total of 31
(21.8%) patients died during follow-up period.
Sera from 128 healthy volunteers (95 males, 33
females) with ages ranging from 21 to 77 years (mean:
47.8 years) were collected and used as controls.
Healthy controls were selected from an archive of
blood samples, and the control samples were matched
as closely as possible to the NPC group with respect
to previous handling and the time period of sample
collection.
A 5-ml blood sample from each participant was
allowed to clot for 30 to 60 min at room temperature.
Each clotted sample was centrifuged at 1500 g for
10 min. All sera were then aliquoted and frozen at
−80 °C until use.
Paraffin-embedded tumour tissue samples were ob-
tained from 20 NPC patients who underwent surgery be-
tween May and December of 2013. None of the patients
had received anticancer treatment prior to surgery, and
all of the patients had histologically confirmed primary
NPC in this retrospective study.
All of the blood and tissues sample were collected at
the Cancer Center of Sun Yat-sen University. The study
was approved by the Ethics Committee of Sun Yat-sen
University Cancer Center and informed consent was ob-
tained from each patient.
Cytokine array
Eight IGF system members (IGF-1, IGF-2, IGF-1SR,
IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4 and IGFBP-6)
were quantified in the plasma of 10 NPC patients and
healthy volunteers using the RayBio Human Cytokine
Antibody Array (#AAH-CYT-5, RayBiotech Inc, GA,
USA) according to the manufacturer’s instruction.
Cell culture
Two well-differentiated NPC cell lines CNE1 and HK1,
three poorly-differentiated NPC cell lines (CNE2,
HONE1, SUNE1) and two SUNE-1 subclones (6–10B
and 5–8 F) were cultured in DMEM medium (Sigma,
Saint Louis, MO, USA). Two undifferentiated NPC cell
lines, C666-1 (EBV-positive) and SUNE2 (extremely low
concentrations of EBV), were cultured in RPMI 1640
medium (Sigma). Immortalized nasopharyngeal epithe-
lial (NPE) cell lines (N5-Tert, N5Bmi-1, N2-Bmi-1) and
normal NPE cell lines (NP460) were cultured in
Keratinocyte-SFM medium (10744–019, Gibco) and
used as a control. All of the cell lines were maintained
in our laboratory, and all media were supplemented with
10% foetal bovine serum (Sigma).
RNA preparation and quantitative real-time PCR
Total RNA was extracted from NPC and nasopharyngeal
epithelial cells lines using the Trizol reagent (Invitrogen,
USA) according to the manufacturer’s instruction. Re-
verse transcription of total RNA (2 μg) was performed
using SuperScript II reverse transcriptase (GIBCO BRL,
Grand Island, NY, USA). The quantification of target
and reference glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) genes was performed using the Power
SYBR Green qPCR SuperMix-UDG (Invitrogen, USA)
on an iCycler (Bio-Rad, Hercules, CA, USA). CT is de-
fined as the cycle at which the fluorescence is deter-
mined to be statistically significant above background.
The relative mRNA expression was normalized to the
expression of GAPDH, which yielded a 2-ΔCT value
(ΔCT = CT(target gene)–CT(GAPDH)). All reactions were
performed in triplicate in three independent experi-
ments. The primers used for real-time RT-PCR were as
follows: IGF-1: forward 5′- GCT CTT CAG TTC GTG
TGT GGA −3′ and reverse 5′- GCC TCC TTA GAT
CAC AGC TCC −3′; IGFBP-1: forward 5′-CTA TGA
TGG CTC GAA GGC TC-3 ′ and reverse 5′-CCC ATT
CCA AGG GTA GAC G-3′; GAPDH: forward 5′-GCA
CCG TCA AGG CTG AG AAC-3′ and reverse 5 ′-TGG
TGA AGA CGC CAG TGG A-3′.
Western blot
Total protein was extracted using a lysis buffer and
protease inhibitor (Beyotime Biotechnology, China).
Equivalent protein amounts were denatured in an SDS
sample buffer and then were separated by SDS-PAGE
and transferred onto polyvinylidene difluoride mem-
brane. After being blocked with 5% non-fat dry milk in
PBS containing 0.05% Tween-20, the blotted mem-
branes were incubated with anti-human IGF-1 and
IGFBP-1 antibodies, (1:5000, 1:1000, respectively, R&D
systems, USA) and then incubated with a secondary
antibody (1:5000, Boster, China). GAPDH protein levels
were also determined by using the specific antibody
(1:1000, Boster, China) as a loading control.
Immunohistochemistry
Formalin-fixed, paraffin-embedded NPC sections were
incubated with a goat polyclonal anti-IGF-1 (1:100, AF-
291-NA, R&D, USA) or anti-IGFBP-1 antibody (1:100,
AF871, R&D, USA) overnight at 4 °C. After washing in
PBST, the tissue sections were treated with a horseradish
peroxidase-conjugated anti-goat secondary antibody
(1:1000, Zymed). The tissue sections were then devel-
oped with 3-diaminobenzidine tetrahydrochloride for
10 s, followed by counterstaining with 10% Mayer’s
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haematoxylin. The degree of staining was reviewed by
two independent observers.
ELISA
Serum IGF-1 and IGFBP-1 levels were determined by
double-antibody sandwich ELISA according to the man-
ufacturer’s instructions (DY291, DY871, R&D systems,
USA). Briefly, 96-well microplates were coated with
100 μl/well of the capture antibody (mouse anti-human
IGF-1 or IGFBP-1, 4.0 μg/ml) overnight at 4 °C. After
blocking with 3% BSA, 100 μl of the test samples (1:100
diluted in 1% BSA) was added and incubated for 2 h at
room temperature. Subsequently, 100 μl/well of the de-
tection antibody (biotinylated goat anti-human IGF-1
(150 ng/ml) or IGFBP-1(400 ng/ml)) was added and in-
cubated for 2 h at room temperature. Next, 100 μl/well
of Streptavidin-HRP (1:200) was added and incubated
for 20 min at room temperature. Finally, the substrate
(tetramethylbenzidine) solution was added, and the reac-
tion was terminated using 2 N H2SO4 and read at an
OD of 450 nm. Each test included a standard control
(CV = 12%).
Statistical analysis
All statistical analyses were carried out using the SPSS
20.0 statistical software package (SPSS Inc., Chicago,
IL). The Mann–Whitney U test was used to evaluate
the difference in IGF-1 and IGFBP-1 serum levels
between NPC patients and healthy controls. Pearson's
chi-squared test was used to analyse the association
between IGF-1 and IGFBP-1 levels and the observed
clinicopathological characteristics of patients with NPC.
Survival curves were plotted by the Kaplan-Meier
method and compared using the log rank test. The
significance of various variables for survival was analysed
using the Cox proportional hazards model (univariate and
multivariate analysis). P < 0.05 was considered to be statis-
tically significant in all cases.
Results
Circulating levels of IGF-related cytokines differ between
NPC patients and healthy control individuals
The plasma level of eight members of the IGF system,
including IGF ligands (IGF-1 and IGF-2), IGF-1 sol-
uble receptor (IGF-1 sR), and IGF binding protein
(IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, and IGFBP-6)
were detected in healthy controls and patients with
NPC (n = 10, respectively) using a Human Cytokine
Antibody Array (Fig. 1). The levels of IGF-1 and IGF-2
from NPC patients were significantly lower compared to
healthy control individuals (P = 0.012, P = 0.046, respect-
ively). Interestingly, while the plasma level of IGFBP-1
from NPC patients was significantly higher than in healthy
control volunteers (P = 0.034), no significant differences
were observed between the plasma levels of the other IGF
soluble receptor or binding proteins, including IGF-1SR,
IGFBP-2, IGFBP-3, IGFBP-4 or IGFBP-6. Fourthermore,
serum level of IGF-1, IGF-2 and IGFBP-1 were analyzed
by ELISA in preliminary experiments (n = 24), there was
no significant difference in serum IGF2 level between
NPC patients and health group. Together, these results
suggest that NPC patients display increased circulating
levels of IGFBP-1 and decreased levels of IGF-1.
Characterization of IGFBP-1 and IGF-1 expression in NPC
and NPE cell lines
Real-time PCR and western blot analysis showed that
IGFBP-1 and IGF-1 were differentially expressed at both
Fig. 1 Characterization of plasma IGF-related cytokines levels in NPC patients and control individuals. Plasma levels of the following cytokines
were analysed in NPC patient and control sera: a IGF-1; b IGF1-sR; c IGF-2 d IGFBP-1; e IGFBP-2; f IGFBP-3; g IGFBP-4; h IGFBP-6
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the mRNA and protein level in 9 NPC cell lines (CNE1,
CNE2, HONE1, HK1, SUNE1, 6–10B and 5–8 F, C666
and SUNE2) and 4 NPE cell lines (N5-Tert, N5-Bmi-
1,N2-Bmi-1 and NP460) (Fig. 2a-c). IGFBP-1 mRNA and
protein were expressed in most of the NPC cell lines,
with the exception of HONE1. CNE1 cells had the high-
est level of IGFBP-1, and moderate or weaker levels of
expression were observed in the other 6 NPC cell lines.
However, IGFBP-1 expression was not detected in any of
the four NPE cell lines. In addition, ELISA analysis of
cell supernatant showed that the secretory level of
IGFBP-1 was below the detection limit in most the cell
lines, with the exception of CEN1 (Fig. 2c).
IGF-1 mRNA and protein were detected in only 5
NPC cell lines, with the highest expression level of
IGF-1 observed in C666 cells, which consistently har-
bours Epstein-Barr virus (EBV), and weaker expression
of IGF-1 detected in three poorly differentiated NPC
cell lines (CNE2, 5-F8, SUNE2) and well-differentiated
cell lines CNE1. IGF-1 expression was shown to be ab-
sent in the other 4 NPC cell lines. Moreover, mRNA
and protein levels of IGF-1 were expressed at moderate
levels in the immortalized NPE cell line, N5Bmi-1, but
not in the other 3 NPE cell lines. ELISA analysis
showed that detectable secretory IGF-1 only in C666
cell line.
Those results showed that the stronger expression of
IGFBP-1 in tumour cell lines than the normal cell lines,
but weak expression of IGF-1 in both of tumour and
normal cell lines.
Characterization of IGFBP-1 and IGF-1 expression
in NPC tissues
We examined the expression of IGFBP-1 and IGF-1 in
16 paraffin-embedded archived NPC tissues by immuno-
cytochemistry. IGFBP-1 protein was detected in all of
the 16 NPC tumour tissues (100%) and in 3 of the 16
normal adjacent tissues (18.75%). Immunostaining of
IGFBP-1 was mainly detected in the nuclei of cancer
cells and cytoplasm of normal cells, with stronger
IGFBP-1 immunostaining present in tumour tissues
compared to peritumoural tissues (Fig. 3a-c). In addition,
IGF-1 protein was detected in 6 of the 16 NPC tumour
tissues (37.5%) and in 14 of the 16 tumour-adjacent nor-
mal tissues (87.5%) with varied IGF-1 immunoreactivity.
IGF-1 was shown localize to the cytoplasm of malignant
tumour cells and surrounding stromal cells, while stron-
ger cytoplasmic staining of IGF-1 was observed in the
normal epithelial and stromal cells of adjacent non-
tumourous tissue (Fig. 3d-f ). Together, these results il-
lustrate that IGFBP-1 is strongly expressed in tumour
tissue, while IGF-1 expression is elevated in normal
tissue.
Serum levels of IGFBP-1 and IGF-1 correlate with distinct
NPC clinicopathological characteristics
The serum levels of IGFBP-1 and IGF-1 were measured
in healthy control individuals (n = 128) and NPC pa-
tients (n = 142), respectively (Fig. 4). The mean concen-
tration of serum IGFBP-1 levels in NPC cases (55.23 ±
41.25 μg/L) was significantly higher compared to control
Fig. 2 Expression of IGFBP-1 and IGF-1 in NPC and immortalized nasopharyngeal epithelial cell lines. RNA or protein was harvested from NPC and
immortalized nasopharyngeal epithelial cell lines and characterized for mRNA expression of a IGFBP-1 and b IGF-1, and protein expression of
IGFBP-1 and IGF-1 in culture medium c or cells d
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cases (32.08 ± 29.73 μg/L, P < 0.001) (Fig. 4a). In con-
trast, the mean concentration of serum IGF-1 levels in
NPC cases (98.14 ± 71.48 μg/L) was significantly lower
compared to control cases (164.01 ± 92.08 μg/L, P =
0.01) (Fig. 4b). The ratio of IGFBP-1/IGF-1 in NPC
patient serum was shown to be significantly higher
compared to control volunteers (P = 0.002) (Fig. 4c).
Next, we assessed the potential correlation between
serum levels of IGFBP-1, IGF-1 and clinical parameters,
including tumour node metastasis (TNM) stage, tumour
size, lymphoid nodal states, clinical stage, etc. The level
of serum IGFBP-1 significantly correlated with age (P =
0.020), WHO histological classification (P = 0.044) and
titre of EA (EBV early antigen-IgA) of NPC (P = 0.015).
In addition, IGF-1 serum levels were shown to signifi-
cantly correlate with gender, but not with other clinical
parameters, and the mean level of IGF-1 in female
patients was higher than in males (P = 0.018). Further-
more, we found that the IGFBP-1/IGF-1 ratio significantly
correlated with age (P = 0.016), WHO histological
classification (P = 0.048) and titre of EA of NPC (P =
0.016). Table 2 shows the relationship between clinico-
pathological data of patients with NPC and the serum
levels of IGFBP-1, IGF-1, and IGFBP-1/IGF-1 ratio.
Prognostic significance of serum IGF-1 and IGFBP-1 levels
in NPC patients
Patients were classified into two groups according to
their mean IGFBP-1 level (<55.23 μg/L vs. ≥ 55.23 μg/L)
and IGFBP-1/IGF-1 ratio (1:1), respectively. The OS and
RFS of patients with NPC were plotted using the
Kaplan-Meier method, and a log-rank test was employed
to evaluate the prognostic significance of IGFBP-1 levels
and IGFBP-1/IGF-1ratio. The group with lower
IGFBP-1 levels (<55.23 μg/L) displayed a significantly
better 5-year survival rate compared to the group with
higher IGFBP-1 levels (≥55.23 μg/L; Fig. 5a-b). The
cumulative 5-year survival rate in the lower IGFBP-1
group was 87.6% compared to the 71.4% rate observed
in the higher IGFBP-1 group (P = 0.038). Kaplan-
Fig. 3 Expression analysis of IGFBP-1 and IGF-1 in NPC by immunohistochemistry. NPC slides were process for immunohistochemistry of IGFBP-1
and IGF-1 and the following observations were made: a-g. (×200). a Negative stain of IGFBP-1 in NPC tissues. b Low expression level of IGFBP-1
in adjacent non-tumourous tissue. c High expression level of IGFBP-1 in NPC tissues. d Negative stain of IGF-1 in NPC tissues. e Low expression of
IGF-1 in NPC tissues. f High expression of IGF-1 in adjacent non-tumourous tissue. Bar, 50 μm
Fig. 4 Comparison of serum levels of IGFBP-1, IGF-1 and r IGFBP-1/IGF-1 in NPC and control groups. Serum levels were quantified from NPC and
control patients of a serum IGFBP-1 level, b serum IGF-1 level and c Ratio of serum IGFBP-1 to IGF-1
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Meier survival analysis revealed that higher serum
IGFBP-1 levels significantly correlated with adverse
RFS (P = 0.046) and OS (P = 0.038). Serum IGF-1 levels
did not correlate with RFS or OS (data not shown).
The IGFBP-1/IGF-1 ratio was shown to significant
correlate with RFS and OS (P = 0.037, P = 0.009,
respectively).
To determine whether IGFBP-1 levels or the IGFBP-1/
IGF-1 ratio could potentially be used as an independ-
ent prognostic factor for NPC patient outcome, we
performed a multivariate analysis for survival using a
multivariate Cox regression model with respect to OS
and RFS (Table 3). Gender (P = 0.042; P = 0.022),
lymphoid nodal states (P = 0.050; P = 0.023) and local-
regional relapse (P = 0.047; P < 0.001), metastasis (P =
0.006; P = 0.028), and the IGFBP-1/IGF-1 ratio (P =
0.035; P = 0.044) significantly correlated with OS and
RFS. Thus, our findings indicate that the ratio of
IGFBP-1/IGF-1 represents an independent prognostic
factor for NPC outcome.
Discussion
Here, our study showed that patients with NPC display
significantly higher serum levels of IGFBP-1 and signifi-
cantly lower serum levels of IGF-1 compared to healthy
control individuals. Moreover, we observed that higher
serum IGFBP-1 levels and an IGFBP-1/IGF-1 ratio sig-
nificantly correlated with decreased overall survival.
Table 2 Clinicpathological associations of IGF-1 and IGFBP-1 expression levels and IGF-1/IGFBP-1
Variables Cases IGFBP-1(ng/L) Significance IGF-1(ng/L) Significance IGFBP-1/IGF-1 Significance
(n) (Mean ± SD) (P)* (Mean ± SD) (P)* >1 ≤1 (P)*
Gender
Male 118 55.08 ± 41.66 0.966 88.26 ± 60.75 0.018* 38 80 0.202
Female 24 55.93 ± 40.05 135.98 ± 88.78 4 20
Age (y)
< 46 73 47.18 ± 36.51 0.020* 103.65 ± 69.31 0.217 16 57 0.016*
≥ 46 69 63.85 ± 44.47 89.02 ± 66.48 28 41
Tumor size
T1 + T2 27 47.54 ± 36.71 0.260 87.09 ± 55.78 0.437 7 20 0.528
T3 + T4 115 57.01 ± 42.18 100.71 ± 74.63 37 78
Lymphoid nodal states
N0-1 76 51.02 ± 41.80 0.156 96.69 ± 75.17 0.946 20 56 0.197
N2-3 66 59.99 ± 40.41 99.79 ± 67.59 24 42
Clinical Stage
1 + 2 15 39.11 ± 37.45 0.101 99.42 ± 58.73 0.853 3 12 0.498
3 + 4 127 57.11 ± 41.40 97.99 ± 73.02 41 86
Local-regional relapse
Yes 16 49.59 ± 39.68 0.537 117.07 ± 88.62 0.198 4 12 0.793
No 126 55.94 ± 41.55 95.76 ± 69.08 40 86
Metastasis
Yes 4 43.16 ± 41.80 0.542 58.52 ± 27.71 0.263 1 3 0.775
No 138 55.96 ± 41.20 97.42 ± 68.94 43 95
WHO histological classification
NKUC 131 57.05 ± 41.94 0.044* 98.25 ± 73.73 0.978 44 87 0.048*
NKDC 11 38.18 ± 25.70 96.88 ± 36.79 0 11
EA
≤ 1:10 53 44.34 ± 36.35 0.015* 104.31 ± 78.59 0.431 10 43 0.016*
> 1:10 89 61.64 ± 42.79 94.51 ± 67.14 34 55
VCA
≤ 1:40 14 57.45 ± 43.73 0.860 102.20 ± 50.26 0.736 2 12 0.263
> 1:40 128 55.39 ± 41.05 95.68 ± 70.16 42 86
*P < 0.05, as determined by Pearson’s Χ2 test
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In this study, IGF-1 was more weakly expressed in the
majority of nasopharyngeal tumour and normal epithe-
lial cell lines, which is in line with previous studies
showing that IGF-1 expression is lower in EBV-negtive
NPC cell lines [15]. In addition, IGF-1 expression was
also weaker in NPC tumour tissues compared to adja-
cent normal tissues. Together, these results are consist-
ent with the lower IGF-1 serum levels observed in NPC
patients compared to the healthy controls in our study.
Our result that IGF-1 is reduced in NPC patients
contradicts those of other studies showing that serum
IGF-1 levels are elevated in cancer patients. High serum
concentrations of IGF-1 have been associated with an
increased risk of breast, prostate, colorectal and HCC
[16, 17]. However, expression of IGF-1 appears to be in-
consistent across different types of tumours. For ex-
ample, IGF-1 protein expression has not been detected
in the serum of patients with adrenocortical carcinoma
[18], and IGF-1 mRNA levels are weak or absent in
oesophageal squamous cell carcinoma cell lines [19].
Moreover, no alterations in IGF-1 mRNA levels are
found in head and neck squamous cell carcinoma
(HNSCC) [20]. However, in line with our findings,
lower serum levels of IGF-1 have been reported in oral
cancer patients compared to healthy controls [14]. In
addition, reduced IGF-1 serum levels have been re-
ported in epithelial ovarian cancer [21] and lower IGF-
1 mRNA levels have been observed in HCC compared
to corresponding non-malignant liver tissues [22].
Thus, it is possible that serum levels of IGF-1 are
dependent on the type of tumour, as well as the local
release ratio of IGF-1.
Although IGF-1 functions as an epithelial cell mitogen
and has been in implicated in cancer development [23],
increased IGF-1 levels have not been associated with
tumour malignancy in some models. For example, hep-
atic IGF-I-deficient mice with reduced circulating IGF-I
levels showed a reduced incidence of colon and breast
Fig. 5 Kaplan-Meier survival analysis in patients with NPC. a, b Overall survival and Relapse-free survival curves for patients according to serum
level of IGFBP-1. c, d Overall survival and relapse-free survival curves for patients according to the ratio level of IGFBP-1 to IGF-1 serum levels
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tumorigenesis [24, 25]; however, this effect was not ob-
served in models of prostate cancer or osteosarcoma
[26, 27]. Furthermore, transgenic mice with modestly
increased serum IGF-I levels did not show an increased
onset or progression of breast tumorigenesis [28].
These results contradict a previous study showing that
higher IGF-1 levels were associated with cancer mortal-
ity [16], but are consistent with our NPC study, sug-
gesting that IGF-1 may play an important role in the
development and progression of specific tumour types,
such as NPC.
IGFBP-1 is a hepatocyte-derived secreted protein that
undergoes various phosphorylation events and localizes
to the nucleus and/or cytoplasm in hepatocellular car-
cinoma [29, 30]. In our study, however, IGFBP-1 was
mainly observed within the nucleus of cancer cells and
in the cytoplasm of normal cells, which is consistent
with previous work showing nuclear localization of
IGFBP −2, −3 -5, and −6 in tumour cells [29, 30].
By binding and sequestering IGF-1, IGFBP-1 antago-
nized IGF-1 which could stimulate the proliferation of
cancer cells [31]. However, accumulating evidence sup-
ports the idea that IGFBPs may drive cancer, rather than
exert tumour suppressive functions in some tumour
types. For example, IGFBP-2 induction has been shown
to activate cell invasion, and increased levels of IGFBP-2
have been reported in ovarian tumour tissues and serum
[21], as well as increased IGFBP-3 mRNA expression in
HNSCC compared to healthy tissue [20]. In our study,
an increased serum level of IGFBP-1 was detected in pa-
tients with NPC, which is consistent with findings ob-
served for oral cancer [8], which suggests that IGFBP-1
may play a cancer-promoting role in NPC rather than a
tumour-suppressing role.
Although clear evidence that tumour growth or migra-
tion is stimulated by IGFBP-1 is still lacking, IGFBP-1 has
also been repored to have IGF-independent actions, such
as activating α5β1 integrin [32]. Preclinical in vivo work
Table 3 Multivariate Cox regression analysis for OS of 142 patients with NPC
Characteristic Overall Survival Relapse-Free Survival
HR 95% CI P value HR 95% CI P value
Gender
Male vs. Female 0.225 0.053–0.950 0.042* 0.247 0.075–0.819 0.022*
Age (y)
< 46 vs. ≥46 1.389 0.673–2.867 0.374 2.099 1.027–4.293 0.042*
Tumor size
T1 + T2 vs. T3 + T4 0.873 0.292–2.611 0.809 0.972 0.325–2.905 0.959
Lymphoid nodal states
N0-1 vs. N2-3 2.312 0.969–5.519 0.050* 2.662 1.146–6.187 0.023*
Clinical Stage
1 + 2 vs. 3 + 4 0.798 0.327–1.945 0.619 0.856 0.284–2.579 0.783
Local-regional relapse
Yes vs. NO 2.296 1.013–5.204 0.047* 23.877 9.554–59.668 0.000*
Metastasis
Yes vs. No 9.085 1.871–44.128 0.006* 5.045 1.195–21.288 0.028*
WHO histological classification
NKUC vs. NKDC 0.680 0.148–3.121 0.620 0.580 0.129–2.609 0.477
EA
≤ 1:10 vs. >1:10 0.568 0.234–1.381 0.212 0.679 0.275–1.677 0.401
VCA
≤ 1:40 vs. >1:40 0.613 0.207–1.816 0.377 0.376 0.131–1.084 0.070
IGFBP-1
Low vs. High 0.802 0.330–1.947 0.626 0.520 0.213–1.267 0.150
IGF-1
Low vs. High 1.649 0.612–4.443 0.323 1.450 0.602–3.490 0.407
IGFBP-1/IGF-1
> 1 vs. ≤1 0.298 0.096–0.920 0.035* 0.334 0.115–0.969 0.044*
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has shown that deletion of IGFBP-I in the c-Myc trans-
genic mouse model resulted in decreased proliferation of
prostatic tissue but had no effect on the development of
prostate cancer [33]. Recently, one study showed that high
expression levels of MMP9 and IGFBPs were associated
with poor prognosis in patients with breast cancer [34]. In
contrast, high expression of IGFBPs was associated with a
favorable prognosis in patients with breast cancer when
MMP9 was expressed at low levels. Their study suggests
that in the presence of high MMP9 levels, IGFBP is
digested, and then IGF is released and activates IGF signal-
ing pathways that promote tumorigenesis in breast cancer.
Because studies indicate that high levels of MMP9 expres-
sion are observed in most NPC tissues [35], the interaction
between MMP9 and IGFBP-1 in NPC tumours may con-
tribute to NPC patients with higher levels of IGFBP-1 and
an unfavourable survival. While this represents an attractive
hypothesis, the underlying mechanism remains unclear and
should be investigated by further studies.
In addition, the balance between IGFs and IGFBPs may
represent an important factor in tumour progression [23].
While higher levels of IGF-I and IGF-I/IGFBP-3 ratio are
associated with an increased risk of death from breast can-
cer and CRC [36, 37], alternative findings have been ob-
served in other studies. For example, elevated IGFBP-2 and
reduced IGF-1 levels or high levels of an IGFBP-2/IGF-1
ratio were shown to stratify an ovarian cancer patient sub-
group with poor prognosis [21]. Similar to this result, our
study showed that a higher IGFBP-1/IGF-1 ratio predicts
NPC patients with unfavourable survival. Our data indicate
that IGFBP-1 may play a more important role in NPC pro-
gression than IGF-1.
Iwakiri et al. reported that EBV infections induce the
expression of IGF-1 mRNA and support the growth of
NPC-derived cell lines [15]. EBV latent membrane pro-
tein 1 (LMP1) selectively activates IGF1R by increasing
IGF-1 expression and alters the phosphorylation of
IGF1R, but not the expression [38]. However, increasing
levels of IGF-1 have not been associated with EA or
VCA-titre levels in NPC patients in our data, although
the EBV-positive C666 cell lines were characterized by
higher IGF-1 expression, which is in line with Iwakiri’s
findings regarding EBV-positive NPC cell lines [15],
suggesting that the circulating levels of IGF-1 are in-
consistent with IGF-1 expression after EBV infection in
vitro. However, the increasing level of IGFBP-1 was as-
sociated with EA-positive, but not VCA-positive NPC
sera, suggests that the association of EBV infection and
the role of IGFs in NPC require further investigation.
Taken together, our study shows that higher serum
IGFBP-1 levels and IGFBP-1/IGF-1 ratio correlate signifi-
cantly with decreased overall survival in NPC patients. Fur-
ther validation of these results is needed to determine the
potential usefulness of these biomarkers for risk assessment.
Conclusions
Our data reveal that IGFBP-1 expression is upregulated in
NPC cell lines and NPC tumour tissues and that IGFBP-1
serum levels are elevated in NPC patients. In addition, we
showed that IGF-1 is more weakly expressed in NPC cell
lines and tumour tissues and that decreasing serum levels
of IGF-1 are observed in NPC patients. Furthermore, we
observed that elevated serum levels of IGFBP-1 were
significantly associated with shorter OS and RFS in
NPC patients. Moreover, higher levels of IGFBP-1 and
lower levels of IGF-1 were shown to predict worse out-
come in NPC patients, suggesting that the ratio of
serum IGFBP-1/IGF-1 represents a potential biomarker
for NPC patient prognosis. These findings also high-
light the more complex biological activities of IGFBP-1
and IGF-1 and reinforce the need to further clarify the
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